Kashiv BioSciences Acquired by Amneal | Healthcare M&A Deal

Amneal has agreed to acquire Kashiv BioSciences, a pharmacy business in New Jersey, for $375 million. Amneal acquisitions target Kashiv BioSciences, a U.S.-based biosimilars company with end-to-end capabilities across development and manufacturing, plus a pipeline of biosimilar candidates. The strategic acquisition supports a platform acquisition strategy for healthcare M&A, expanding Amneal’s global biosimilars footprint and strengthening biologics loss-of-exclusivity positioning. The healthcare deals NJ transaction is structured as a strategic acquisition with consideration including $375 million cash and $375 million equity at closing, plus up to $350 million tied to regulatory milestones and additional commercial royalties.